AstraZeneca PLC (LON:AZN)

Market Cap	178.37B +3.6%
Revenue (ttm)	46.25B +8.6%
Net Income	7.87B +25.9%
EPS	5.03 +25.8%
Shares Out	1.55B
PE Ratio	22.84
Forward PE	14.22
Dividend	2.39 (2.08%)
Ex-Dividend Date	Aug 6, 2026

Volume	n/a
Open	11,728
Previous Close	11,500
Day's Range	11,670 - 11,812
52-Week Range	10,524 - 15,732
Beta	0.22
Analysts	Buy
Price Target	15,844.49 (+35.24%)
Earnings Date	Jul 27, 2026

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 96,100
• Stock Exchange: London Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Financial numbers in USD

Analyst Summary

According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,844p, which is an increase of 35.24% from the latest price.

Price Target

15,844p

(35.24% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 4, 2026

Data Sources Report a data error